In a new interview, Biostock talk with Otto Skolling, who was recently elected Vice Chairman of the Board of Chordate Medical. Otto Skolling has over 30 years of experience in product development, business development and project management within the pharmaceutical and medical technology industry.
“I am quite new to the company, so it is likely that I do not yet see all the opportunities and potential that the company has. However, it is clear to everyone that a new treatment in migraine for all those patients who do not respond to existing drugs, and it is a large group, with an effect on par with the best is of course very exciting. Here I believe that Chordate has an opportunity to become a serious alternative for those who today do not respond to existing drugs or who do not want to use these heavy drugs that are associated with today’s migraine treatment”, says Otto Skolling to Biostock.